Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective

Critical Reviews in Microbiology

Volumn 42, Issue 1, 2016, Pages 1-16

  Biehl, Lena M ^a   Schmidt Hieber, Martin ^b   Liss, Blasius ^a   Cornely, Oliver A ^a,c,d   Vehreschild, Maria J G T ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c German Centre for Infection Research (DZIF)   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Bloodstream infection; colonization; ESBL; ICU; malignancy; neutropenia

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG USE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; EVIDENCE BASED PRACTICE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAFT RECIPIENT; GRAM NEGATIVE BACTERIUM; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; INFECTION CONTROL; INFECTION RISK; KLEBSIELLA PNEUMONIAE; LIVER GRAFT; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; BACTEREMIA; BIOSYNTHESIS; CROSS INFECTION; DISEASE MANAGEMENT; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; META ANALYSIS; MICROBIOLOGY; OUTCOME ASSESSMENT; RISK;

BACTEREMIA; BETA-LACTAMASES; CROSS INFECTION; DISEASE MANAGEMENT; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; PATIENT OUTCOME ASSESSMENT; PREVALENCE; RISK;

EID: 84959341617     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2013.875515     Document Type: Review

References (75)

1. Abad C, Fearday A, Safdar N. (2010). Adverse effects of isolation in hospitalised patients: a systematic review. J Hosp Infect 76: 97-102
2. Abecasis F, Sarginson RE, Kerr S, et al. (2011). Is selective digestive decontamination useful in controlling aerobic Gram-negative bacilli producing extended spectrum beta-lactamases? Microb Drug Resist 17: 17-23
3. Al Naiemi N, Heddema ER, Bart A, et al. (2006). Emergence of multidrug-resistant Gram-negative bacteria during selective decontamination of the digestive tract on an intensive care unit. J Antimicrob Chemother 58: 853-6
4. Ariffin H, Navaratnam P, Kee TK, Balan G. (2004). Antibiotic resistance patterns in nosocomial Gram-negative bacterial infections in units with heavy antibiotic usage. J Trop Pediatr 50: 26-31
5. Arnan M, Gudiol C, Calatayud L, et al. (2011). Risk factors for, and clinical relevance of, faecal extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 30: 355-60
6. Azim A, Dwivedi M, Rao PB, et al. (2010). Epidemiology of bacterial colonization at intensive care unit admission with emphasis on extended-spectrum beta-lactamase- and metallo-beta-lactamase-producing Gram-negative bacteria-an Indian experience. J Med Microbiol 59: 955-60
7. Bassetti M, Righi E, Fasce R, et al. (2007). Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother 60: 433-5
8. Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. (2006). Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 42: 925-34
9. Bert F, Larroque B, Paugam-Burtz C, et al. (2012). Pretransplant fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and infection after liver transplant, France. Emerg Infect Dis 18: 908-16
10. Bertrand X, Dowzicky MJ. (2012). Antimicrobial susceptibility among Gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Ther 34: 124-37
11. Bin C, Hui W, Renyuan Z, et al. (2006). Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 56: 351-7
12. Blijlevens NM, Donnelly JP, de Pauw BE. (2000). Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 25: 1269-78
13. Calatayud L, Arnan M, Linares J, et al. (2008). Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer. Antimicrob Agents Chemother 52: 4187-90
14. Chopra T, Marchaim D, Veltman J, et al. (2012). Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 56: 3936-42
15. Christiaens G, Ciccarella Y, Damas P, et al. (2006). Prospective survey of digestive tract colonization with enterobacteriaceae that produce extended-spectrum beta-lactamases in intensive care units. J Hosp Infect 62: 386-8
16. Cordery RJ, Roberts CH, Cooper SJ, et al. (2008). Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. J Hosp Infect 68: 108-15
17. Cornely OA, Schirmacher P. (2001). Clinical picture: bacterial translocation in neutropenic sepsis. Lancet 358: 1842
18. Daoud Z, Moubareck C, Hakime N, Doucet-Populaire F. (2006). Extended spectrum beta-lactamase producing Enterobacteriaceae in Lebanese ICU patients: epidemiology and patterns of resistance. J Gen Appl Microbiol 52: 169-78
19. de Jonge E, Schultz MJ, Spanjaard L, et al. (2003). Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 362: 1011-16
20. de Smet AM, Kluytmans JA, Blok HE, et al. (2011). Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 11: 372-80
21. ECDC. (2012). Antimicrobial resistance surveillance in Europe 2011. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Prevention and Control
22. Endimiani A, Luzzaro F, Perilli M, et al. (2004). Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 38: 243-51
23. Frakking FN, Rottier WC, Dorigo-Zetsma JW, et al. (2013). Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum beta-lactamase producing bacteria. Antimicrob Agents Chemother 57:3092-9
24. Gudiol C, Calatayud L, Garcia-Vidal C, et al. (2010). Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65: 333-41
25. Gudiol C, Tubau F, Calatayud L, et al. (2011). Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66: 657-63
26. Guet-Revillet H, Le Monnier A, Breton N, et al. (2012). Environmental contamination with extended-spectrum beta-lactamases: is there any difference between Escherichia coli and Klebsiella spp? Am J Infect Control 40: 845-8
27. Halaby T, Al Naiemi N, Kluytmans J, et al. (2013). Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother 57:3224-9
28. Hanberger H, Arman D, Gill H, et al. (2009). Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med 35: 91-100
29. Harris AD, Kotetishvili M, Shurland S, et al. (2007). How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition. Am J Infect Control 35: 97-101
30. Harris AD, Nemoy L, Johnson JA, et al. (2004). Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect Control Hosp Epidemiol 25: 105-8
31. Huang SS, Lee MH, Leu HS. (2006). Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella. J Microbiol Immunol Infect 39: 496-502
32. Kader AA, Kumar A, Kamath KA. (2007). Fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 28: 1114-16
33. Kang CI, Chung DR, Ko KS, Peck KR, Song JH. (2012). Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 91: 115-21
34. Kang CI, Kim SH, Kim DM, et al. (2004a). Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 25: 860-7
35. Kang CI, Kim SH, Park WB, et al. (2004b). Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48: 4574-81
36. Kang CI, Wi YM, Ko KS, et al. (2013). Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy. Scand J Infect Dis 45:519-25
37. Kim BN, Woo JH, Kim MN, et al. (2002). Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 52: 99-106
38. Kim SH, Kwon JC, Choi SM, et al. (2013). Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. Ann Hematol 92: 533-41
39. Ko YJ, Moon HW, Hur M, et al. (2013). Fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Korean community and hospital settings. Infection 41:9-13
40. Kola A, Holst M, Chaberny IF, et al. (2007). Surveillance of extended-spectrum beta-lactamase-producing bacteria and routine use of contact isolation: experience from a three-year period. J Hosp Infect 66: 46-51
41. Lan CK, Hsueh PR, Wong WW, et al. (2003). Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms. J Microbiol Immunol Infect 36: 182-6
42. Laurent C, Rodriguez-Villalobos H, Rost F, et al. (2008). Intensive care unit outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae controlled by cohorting patients and reinforcing infection control measures. Infect Control Hosp Epidemiol 29: 517-24
43. Lee CH, Su LH, Tang YF, Liu JW. (2006). Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 58: 1074-7
44. Lee NY, Lee CC, Huang WH, et al. (2012). Carbapenem therapy for bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother 56: 2888-93
45. Lee SO, Lee ES, Park SY, et al. (2004). Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 25: 832-7
46. Liss BJ, Vehreschild JJ, Cornely OA, et al. (2012). Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40: 613-19
47. Meyer E, Lapatschek M, Bechtold A, et al. (2009). Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K pneumoniae and E. coli in an ICU. Intensive Care Med 35: 862-70
48. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. (2010). Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit Care 14: R113
49. Nasa P, Juneja D, Singh O, et al. (2012). An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome. Eur J Intern Med 23: 192-5
50. Oostdijk EA, de Smet AM, Kesecioglu J, Bonten MJ. (2011). The role of intestinal colonization with Gram-negative bacteria as a source for intensive care unit-acquired bacteremia. Crit Care Med 39: 961-6
51. Oostdijk EA, de Smet AM, Kesecioglu J, et al. (2012). Decontamination of cephalosporin-resistant Enterobacteriaceae during selective digestive tract decontamination in intensive care units. J Antimicrob Chemother 67: 2250-3
52. Oteo J, Perez-Vazquez M, Campos J. (2010). Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 23: 320-6
53. Paterson DL, Ko WC, von Gottberg A, et al. (2004). Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 39: 31-7
54. Peralta G, Lamelo M, Alvarez-Garcia P, et al. (2012). Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis 12: 245
55. Pitout JD, Laupland KB. (2008). Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8: 159-66
56. Prospero E, Barbadoro P, Esposto E, et al. (2010). Extended-spectrum beta-lactamases Klebsiella pneumoniae: multimodal infection control program in intensive care units. J Prev Med Hyg 51: 110-15
57. Qureshi ZA, Paterson DL, Pakstis DL, et al. (2011). Risk factors and outcome of extended-spectrum beta-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents 37: 26-32
58. Qureshi ZA, Paterson DL, Potoski BA, et al. (2012). Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56: 2108-13
59. Razazi K, Derde LP, Verachten M, et al. (2012). Clinical impact and risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria in the intensive care unit. Intensive Care Med 38: 1769-78
60. Reddy P, Malczynski M, Obias A, et al. (2007). Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 45: 846-52
61. RKI. (2012). Hygiene measures for infection or colonization with multidrug-resistant Gram-negative bacilli. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55: 1311-54
62. Rodriguez-Bano J, Navarro MD, Retamar P, et al. (2012). beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54: 167-74
63. Rodriguez-Bano J, Navarro MD, Romero L, et al. (2006). Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 42: 37-45
64. Rodriguez-Bano J, Picon E, Gijon P, et al. (2010). Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 48: 1726-31
65. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. (2005). Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 52: 203-8
66. Saidel-Odes L, Polachek H, Peled N, et al. (2012). A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 33: 14-19
67. Thiebaut AC, Arlet G, Andremont A, et al. (2012). Variability of intestinal colonization with third-generation cephalosporin-resistant Enterobacteriaceae and antibiotic use in intensive care units. J Antimicrob Chemother 67: 1525-36
68. To KK, Lo WU, Chan JF, et al. (2013). Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity. Int J Infect 17:e120-4
69. Trecarichi EM, Tumbarello M, Spanu T, et al. (2009). Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58: 299-307
70. Troche G, Joly LM, Guibert M, Zazzo JF. (2005). Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. Infect Control Hosp Epidemiol 26: 161-5
71. Tschudin-Sutter S, Frei R, Dangel M, et al. (2012). Rate of transmission of extended-spectrum Beta-lactamase-producing enterobacteriaceae without contact isolation. Clin Infect Dis 55: 1505-11
72. Tumbarello M, Viale P, Viscoli C, et al. (2012). Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K pneumoniae: importance of combination therapy. Clin Infect Dis 55: 943-50
73. Wassenberg MW, Severs D, Bonten MJ. (2010). Psychological impact of short-term isolation measures in hospitalised patients. J Hosp Infect 75: 124-7
74. Winters HA, Parbhoo RK, Schafer JJ, Goff DA. (2011). Extended-spectrum beta-lactamase-producing bacterial infections in adult solid organ transplant recipients. Ann Pharmacother 45: 309-16
75. Zuckerman T, Benyamini N, Sprecher H, et al. (2011). SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 46: 1226-30